Allergy Testing in Children

Allergy testing in children is a structured diagnostic process used to identify specific substances — allergens — that trigger immune responses ranging from mild skin irritation to life-threatening anaphylaxis. This page covers the primary testing methods used in pediatric practice, the clinical scenarios that prompt referral, and the criteria clinicians use to determine which test type is appropriate for a given patient. Understanding the scope and limitations of each method is essential for interpreting results accurately within a broader pediatric care framework.

Definition and scope

Pediatric allergy testing encompasses a set of procedures designed to confirm or rule out IgE-mediated (immediate hypersensitivity) and non-IgE-mediated (delayed hypersensitivity) immune reactions in patients under 18. The American Academy of Pediatrics (AAP) recognizes allergy evaluation as a component of managing conditions including asthma, allergic rhinitis, atopic dermatitis, food allergy, and drug hypersensitivity.

Allergy is among the most prevalent chronic health conditions affecting children in the United States. According to the CDC National Center for Health Statistics, food allergy affects approximately 6% of children ages 0–17, while respiratory allergies affect roughly 10–12% of the same age group. These prevalence figures make standardized diagnostic protocols critical for avoiding both underdiagnosis and unnecessary dietary or environmental restrictions.

Testing is governed at the practice level by guidelines from the AAP and the American Academy of Allergy, Asthma & Immunology (AAAAI). Regulatory oversight of test devices falls under the U.S. Food and Drug Administration (FDA), which classifies skin test devices under 21 CFR Part 880 as Class II medical devices subject to performance standards.

How it works

Allergy testing in pediatrics follows a tiered diagnostic logic. No single test is universally definitive; results are interpreted alongside clinical history and physical examination findings.

The four principal methods used in pediatric populations are:

1. Skin prick test (SPT) — A small amount of standardized allergen extract is introduced into the superficial skin layer via a lancet or probe. A wheal-and-flare reaction measuring ≥3 mm greater than the negative control at 15–20 minutes constitutes a positive result. The AAAAI identifies SPT as the first-line method for evaluating IgE-mediated allergy due to its speed, low cost, and high sensitivity.

2. Intradermal test (IDT) — A small volume (typically 0.02–0.05 mL) of diluted allergen is injected intradermally. IDT is more sensitive but less specific than SPT and carries a higher risk of systemic reaction. It is generally reserved for venom allergy or drug hypersensitivity evaluation when SPT is negative but clinical suspicion remains high.

3. Serum-specific IgE (ssIgE) testing — A blood draw measures circulating IgE antibodies specific to a given allergen using immunoassay platforms such as ImmunoCAP (Thermo Fisher Scientific) or equivalent. The AAAAI notes ssIgE is preferred when SPT cannot be performed safely — for example, in children with extensive active eczema, dermographism, or those who cannot discontinue antihistamines. Results are reported in kUA/L on a Class 0–6 scale.

4. Oral food challenge (OFC) — Supervised incremental ingestion of a suspected food allergen under medical monitoring. The OFC is considered the gold standard for diagnosing food allergy per NIAID Food Allergy Guidelines and is used to confirm or refute equivocal SPT or ssIgE results. A double-blind, placebo-controlled food challenge (DBPCFC) is the most rigorous variant used in research settings.

Patch testing for contact dermatitis — a delayed, T-cell-mediated reaction — represents a fifth modality used when allergic contact dermatitis is suspected. It differs mechanistically from all four methods above because it targets Type IV hypersensitivity rather than IgE-mediated responses.

Common scenarios

Referral for allergy testing is initiated across a range of pediatric clinical presentations. The most frequent include:

• Recurrent anaphylaxis of unknown cause — An allergist evaluates potential food, drug, insect venom, or latex triggers using SPT and ssIgE panels.
• Suspected food allergy — Positive SPT or ssIgE to peanut, tree nut, milk, egg, wheat, soy, fish, or shellfish prompts consideration of OFC to establish threshold and confirm clinical relevance.
• Asthma with suspected allergic triggers — Per NHLBI Asthma Guidelines, allergen sensitization testing supports asthma management decisions, including allergen immunotherapy eligibility. Children with asthma may undergo aeroallergen panels covering dust mite, mold, cockroach, pet dander, and regional pollen.
• Chronic urticaria or atopic dermatitis — Testing is selectively applied; routine broad food panels are not recommended by the AAAAI for isolated chronic urticaria because yield is low and false positives generate unnecessary dietary restriction.
• Drug hypersensitivity — Penicillin skin testing remains the best-validated drug allergy test in pediatrics; the FDA-cleared Pre-Pen reagent (benzylpenicilloyl-polylysine) is used for major determinant testing.

Children with allergies and concurrent eczema or skin conditions require individualized testing strategies because widespread dermatitis compromises SPT interpretation.

Decision boundaries

The choice between testing modalities — and the decision to test at all — depends on identifiable clinical variables rather than patient or caregiver preference alone.

Key decision factors include:

• Age — SPT can be performed at any age but wheal size may be smaller in infants under 2 years, reducing sensitivity. The regulatory context for pediatric diagnostics informs how FDA-cleared devices are applied across different age groups.
• Skin condition — Active widespread eczema or dermatographism shifts the approach toward ssIgE blood testing.
• Medication status — Antihistamines suppress SPT whealing; tricyclic antidepressants suppress SPT for up to 10 days. ssIgE is unaffected by antihistamine use.
• Anaphylaxis risk — IDT and OFC carry measurable systemic reaction risk and require on-site emergency preparedness including epinephrine availability.
• Positive predictive value thresholds — For peanut, published likelihood ratio data (AAAAI/ACAAI practice parameters) indicate that an ssIgE ≥15 kUA/L correlates with >95% probability of clinical reactivity, potentially obviating OFC in high-risk patients.
• False positive management — SPT and ssIgE sensitization without clinical history of reaction does not constitute clinical allergy. Over-reliance on positive tests without confirmatory OFC leads to unnecessary food elimination, which carries its own nutritional risks in children — particularly in those with nutrition and special health needs.

For children presenting with diagnostic uncertainty that extends beyond allergy — such as overlapping behavioral, developmental, or chronic illness concerns — integrated evaluation pathways are addressed across the pediatric diagnostics literature and aligned subspecialty guidance from organizations including the AAP Section on Allergy and Immunology.

References

• American Academy of Pediatrics (AAP)
• American Academy of Allergy, Asthma & Immunology (AAAAI) — Allergy Testing Overview
• CDC National Center for Health Statistics — Child Health Data
• NIAID Guidelines for the Diagnosis and Management of Food Allergy in the United States (NIH)
• NHLBI National Asthma Education and Prevention Program — Asthma Guidelines
• U.S. FDA — 21 CFR Part 880, General Hospital and Personal Use Devices
• Joint Task Force on Practice Parameters; AAAAI/ACAAI — Allergy Diagnostic Testing: An Updated Practice Parameter

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)